Exscientia completes Series C financing round with BlackRock funds
Exscientia, a clinical stage pharmatech pioneering the use of artificial intelligence (AI) to design new drugs, today announced that funds managed by BlackRock joined the Company’s Series C investment round. The existing Series C investors also include Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital.
This new capital will be used to support Exscientia’s platform development towards autonomous drug design. In addition, the company will extend its proprietary pipeline into clinical trials and expand existing capabilities in biological analytics that support target selection and portfolio development.
BlackRock is one of the world’s leading providers of investment, advisory and risk management solutions. As of December 31, 2021, BlackRock's assets under management total US$8.68 trillion across equity, fixed income, cash management, alternative investment, real estate and advisory strategies.